Clinical Trials
5 trialsNCT04564027 2025-08-29
A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer
AstraZeneca
Phase 2 Completed
NCT05469919 2024-08-02
An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies
AstraZeneca
Phase 1 Completed
NCT02937818 2024-06-07
A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer
AstraZeneca
Phase 2 Completed
NCT03527147 2022-08-15
PRISM
Acerta Pharma BV
Phase 1 Completed
NCT03022409 2021-08-10
A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).
AstraZeneca
Phase 1 Completed